OBJECTIVES: Repeat transarterial chemoembolization (TACE) is a common intervention performed for hepatocellular carcinoma (HCC). The aim of this study was to identify predictors of the need for repeat TACE. METHODS: Between 2008 and 2012, data on patient and tumour variables were collected for 262 patients treated with a first TACE procedure for HCC. The decision to perform repeat TACE procedures was made at the completion of the first TACE or after follow-up imaging demonstrated the subtotal treatment of HCC tumours. RESULTS: Repeat TACE was performed in 67 of 262 (25.6%) patients. Necrosis of HCC, measured after the first TACE, was lower in patients who subsequently received repeat TACE (P = 0.042). On multivariable analysis, total tumour diameter of >5 cm [odds ratio (OR) 2.76, 95% confidence interval (CI) 1.45-5.25; P = 0.002] and increasing age (OR 1.04/year, 95% CI 1.00-1.07; P = 0.030) were predictive of the need for repeat TACE. Measures of liver function and TACE approach (selective versus non-selective) were not predictive of repeat TACE. Median survival did not differ significantly between patients who did (median survival: 21.1 months) and did not (median survival: 26.1 months) receive a repeat TACE procedure (P = 0.574). CONCLUSIONS: The requirement for repeat TACE is associated with older age, increased HCC tumour burden and subtotal TACE-induced HCC necrosis. Importantly, repeat TACE was not associated with reduced survival.
OBJECTIVES: Repeat transarterial chemoembolization (TACE) is a common intervention performed for hepatocellular carcinoma (HCC). The aim of this study was to identify predictors of the need for repeat TACE. METHODS: Between 2008 and 2012, data on patient and tumour variables were collected for 262 patients treated with a first TACE procedure for HCC. The decision to perform repeat TACE procedures was made at the completion of the first TACE or after follow-up imaging demonstrated the subtotal treatment of HCC tumours. RESULTS: Repeat TACE was performed in 67 of 262 (25.6%) patients. Necrosis of HCC, measured after the first TACE, was lower in patients who subsequently received repeat TACE (P = 0.042). On multivariable analysis, total tumour diameter of >5 cm [odds ratio (OR) 2.76, 95% confidence interval (CI) 1.45-5.25; P = 0.002] and increasing age (OR 1.04/year, 95% CI 1.00-1.07; P = 0.030) were predictive of the need for repeat TACE. Measures of liver function and TACE approach (selective versus non-selective) were not predictive of repeat TACE. Median survival did not differ significantly between patients who did (median survival: 21.1 months) and did not (median survival: 26.1 months) receive a repeat TACE procedure (P = 0.574). CONCLUSIONS: The requirement for repeat TACE is associated with older age, increased HCC tumour burden and subtotal TACE-induced HCC necrosis. Importantly, repeat TACE was not associated with reduced survival.
Authors: Thomas J Vogl; Nagy N N Naguib; Nour-Eldin A Nour-Eldin; Pramod Rao; Alborz Hedayati Emami; Stefan Zangos; Mohamed Nabil; Ahmed Abdelkader Journal: Eur J Radiol Date: 2008-10-02 Impact factor: 3.528
Authors: H J Jaeger; U M Mehring; F Castañeda; F Hasse; G Blumhardt; D Loehlein; K D Mathias Journal: Cardiovasc Intervent Radiol Date: 1996 Nov-Dec Impact factor: 2.740
Authors: Riad Salem; Robert J Lewandowski; Mary F Mulcahy; Ahsun Riaz; Robert K Ryu; Saad Ibrahim; Bassel Atassi; Talia Baker; Vanessa Gates; Frank H Miller; Kent T Sato; Ed Wang; Ramona Gupta; Al B Benson; Steven B Newman; Reed A Omary; Michael Abecassis; Laura Kulik Journal: Gastroenterology Date: 2009-09-18 Impact factor: 22.682
Authors: Yuzhu Wang; Junjie Li; Indhumathy Subramaniyan; Goncalo Dias do Vale; Jaideep Chaudhary; Arnida Anwar; Mary Wight-Carter; Jeffrey G McDonald; William C Putnam; Tao Qin; Hongwei Zhang; Ian R Corbin Journal: Toxicol Appl Pharmacol Date: 2020-05-15 Impact factor: 4.219
Authors: Jared A White; Stephen H Gray; Peng Li; Heather N Simpson; Brendan M McGuire; Devin E Eckhoff; Ahmed Mohamed Kamel Abdel Aal; Souheil Saddekni; Derek A Dubay Journal: Hepatol Commun Date: 2017-05-18
Authors: Gauri Mishra; Anouk Dev; Eldho Paul; Wa Cheung; Jim Koukounaras; Ashu Jhamb; Ben Marginson; Beng Ghee Lim; Paul Simkin; Adina Borsaru; James Burnes; Mark Goodwin; Vivek Ramachandra; Manfred Spanger; John Lubel; Paul Gow; Siddharth Sood; Alexander Thompson; Marno Ryan; Amanda Nicoll; Sally Bell; Ammar Majeed; William Kemp; Stuart K Roberts Journal: BMC Cancer Date: 2020-05-29 Impact factor: 4.430
Authors: Nathan Haywood; Kyle Gennaro; John Obert; Paul F Sauer; David T Redden; Jessica Zarzour; J Kevin Smith; David Bolus; Souheil Saddekni; Ahmed Kamel Abdel Aal; Stephen Gray; Jared White; Devin E Eckhoff; Derek A DuBay Journal: J Oncol Date: 2016-02-02 Impact factor: 4.375